Clozapine (N = 32) | Placebo (N = 28) | |
---|---|---|
Values are mean (SD). | ||
*Higher scores indicate more severe impairment; †lower scores indicate more severe impairment. | ||
CGI, clinical global impression scale; MMSE, mini mental test examination; PANSS, positive and negative syndrome scale; PD, Parkinson’s disease; UPDRS, unified Parkinson’s disease rating scale. | ||
Age (years) | 71.2 (7.4) | 72.8 (8.2) |
Sex | ||
Male | 56% | 50% |
Female | 44% | 50% |
Duration of PD (years) | 12.1 (5.7) | 11.3 (5.4) |
Hoehn and Yahr stage | 3.3 (0.9) | 3.1 (1.4) |
UPDRS scores* | ||
Total | 52.6 (21.1) | 52.7 (19.8) |
Motor | 31.5 (14.2) | 31.4 (13.2) |
Schwab and England | 67.4 (20.8) | 70.7 (18.6) |
Levodopa dosage (mg/day) | 788 (390) | 733 (489) |
Positive PANSS* | 17.8 (4.7) | 15.3 (5.0) |
CGI* | 5.1 (0.8) | 4.9 (0.9) |
MMSE† | 26.1 (3.0) | 24.1 (2.8) |